vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and SYNAPTICS Inc (SYNA). Click either name above to swap in a different company.
SYNAPTICS Inc is the larger business by last-quarter revenue ($302.5M vs $247.1M, roughly 1.2× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs -4.9%, a 16.0% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 13.2%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $18.2M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 12.9%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Synaptics, Inc. is an American neural network technologies and computer-to-human interface devices development company based in San Jose, California. It develops touchpads and fingerprint biometrics technology for computer laptops; touch, display driver, and fingerprint biometrics technology for smartphones; and touch, video and far-field voice, low-power AI processors, and wireless technology for smart home devices, wearables, and automobiles. Synaptics sells its products to original equipme...
ANIP vs SYNA — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $302.5M |
| Net Profit | $27.5M | $-14.8M |
| Gross Margin | — | 43.5% |
| Operating Margin | 14.1% | -5.0% |
| Net Margin | 11.1% | -4.9% |
| Revenue YoY | 29.6% | 13.2% |
| Net Profit YoY | 367.5% | -922.2% |
| EPS (diluted) | $1.14 | $-0.38 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $302.5M | ||
| Q3 25 | $227.8M | $292.5M | ||
| Q2 25 | $211.4M | $282.8M | ||
| Q1 25 | $197.1M | $266.6M | ||
| Q4 24 | $190.6M | $267.2M | ||
| Q3 24 | $148.3M | $257.7M | ||
| Q2 24 | $138.0M | $247.4M | ||
| Q1 24 | $137.4M | $237.3M |
| Q4 25 | $27.5M | $-14.8M | ||
| Q3 25 | $26.6M | $-20.6M | ||
| Q2 25 | $8.5M | $-4.7M | ||
| Q1 25 | $15.7M | $-21.8M | ||
| Q4 24 | $-10.3M | $1.8M | ||
| Q3 24 | $-24.2M | $-23.1M | ||
| Q2 24 | $-2.3M | $208.3M | ||
| Q1 24 | $18.2M | $-18.1M |
| Q4 25 | — | 43.5% | ||
| Q3 25 | — | 42.6% | ||
| Q2 25 | — | 43.0% | ||
| Q1 25 | — | 43.4% | ||
| Q4 24 | — | 45.7% | ||
| Q3 24 | — | 46.9% | ||
| Q2 24 | — | 45.8% | ||
| Q1 24 | — | 46.5% |
| Q4 25 | 14.1% | -5.0% | ||
| Q3 25 | 15.9% | -7.9% | ||
| Q2 25 | 6.6% | -8.6% | ||
| Q1 25 | 13.3% | -9.9% | ||
| Q4 24 | -2.3% | -5.7% | ||
| Q3 24 | -13.8% | -11.0% | ||
| Q2 24 | 3.7% | -12.6% | ||
| Q1 24 | 14.8% | -7.3% |
| Q4 25 | 11.1% | -4.9% | ||
| Q3 25 | 11.7% | -7.0% | ||
| Q2 25 | 4.0% | -1.7% | ||
| Q1 25 | 8.0% | -8.2% | ||
| Q4 24 | -5.4% | 0.7% | ||
| Q3 24 | -16.3% | -9.0% | ||
| Q2 24 | -1.7% | 84.2% | ||
| Q1 24 | 13.2% | -7.6% |
| Q4 25 | $1.14 | $-0.38 | ||
| Q3 25 | $1.13 | $-0.53 | ||
| Q2 25 | $0.36 | $-0.13 | ||
| Q1 25 | $0.69 | $-0.56 | ||
| Q4 24 | $-0.45 | $0.05 | ||
| Q3 24 | $-1.27 | $-0.58 | ||
| Q2 24 | $-0.14 | $5.28 | ||
| Q1 24 | $0.82 | $-0.46 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $437.4M |
| Total DebtLower is stronger | — | $836.0M |
| Stockholders' EquityBook value | $540.7M | $1.4B |
| Total Assets | $1.4B | $2.6B |
| Debt / EquityLower = less leverage | — | 0.60× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $437.4M | ||
| Q3 25 | $262.6M | $459.9M | ||
| Q2 25 | $217.8M | $452.5M | ||
| Q1 25 | $149.8M | $421.4M | ||
| Q4 24 | $144.9M | $596.1M | ||
| Q3 24 | $145.0M | $853.6M | ||
| Q2 24 | $240.1M | $876.9M | ||
| Q1 24 | $228.6M | $828.6M |
| Q4 25 | — | $836.0M | ||
| Q3 25 | — | $835.4M | ||
| Q2 25 | — | $834.8M | ||
| Q1 25 | — | $834.2M | ||
| Q4 24 | — | $832.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $983.5M | ||
| Q1 24 | — | — |
| Q4 25 | $540.7M | $1.4B | ||
| Q3 25 | $505.8M | $1.4B | ||
| Q2 25 | $436.8M | $1.4B | ||
| Q1 25 | $418.6M | $1.4B | ||
| Q4 24 | $403.7M | $1.4B | ||
| Q3 24 | $405.9M | $1.5B | ||
| Q2 24 | $455.8M | $1.5B | ||
| Q1 24 | $452.0M | $1.2B |
| Q4 25 | $1.4B | $2.6B | ||
| Q3 25 | $1.4B | $2.6B | ||
| Q2 25 | $1.3B | $2.6B | ||
| Q1 25 | $1.3B | $2.6B | ||
| Q4 24 | $1.3B | $2.5B | ||
| Q3 24 | $1.3B | $2.8B | ||
| Q2 24 | $920.8M | $2.8B | ||
| Q1 24 | $914.5M | $2.5B |
| Q4 25 | — | 0.60× | ||
| Q3 25 | — | 0.60× | ||
| Q2 25 | — | 0.60× | ||
| Q1 25 | — | 0.60× | ||
| Q4 24 | — | 0.60× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.67× | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $29.8M |
| Free Cash FlowOCF − Capex | $29.1M | $18.2M |
| FCF MarginFCF / Revenue | 11.8% | 6.0% |
| Capex IntensityCapex / Revenue | 0.5% | 3.8% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $154.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $29.8M | ||
| Q3 25 | $44.1M | $30.2M | ||
| Q2 25 | $75.8M | $57.2M | ||
| Q1 25 | $35.0M | $73.4M | ||
| Q4 24 | $15.9M | $22.8M | ||
| Q3 24 | $12.5M | $-11.4M | ||
| Q2 24 | $17.4M | $65.0M | ||
| Q1 24 | $18.3M | $-13.7M |
| Q4 25 | $29.1M | $18.2M | ||
| Q3 25 | $38.0M | $18.0M | ||
| Q2 25 | $71.8M | $50.6M | ||
| Q1 25 | $32.5M | $68.0M | ||
| Q4 24 | $13.5M | $18.1M | ||
| Q3 24 | $7.7M | $-20.5M | ||
| Q2 24 | $13.0M | $57.3M | ||
| Q1 24 | $13.7M | $-22.7M |
| Q4 25 | 11.8% | 6.0% | ||
| Q3 25 | 16.7% | 6.2% | ||
| Q2 25 | 34.0% | 17.9% | ||
| Q1 25 | 16.5% | 25.5% | ||
| Q4 24 | 7.1% | 6.8% | ||
| Q3 24 | 5.2% | -8.0% | ||
| Q2 24 | 9.4% | 23.2% | ||
| Q1 24 | 10.0% | -9.6% |
| Q4 25 | 0.5% | 3.8% | ||
| Q3 25 | 2.7% | 4.2% | ||
| Q2 25 | 1.9% | 2.3% | ||
| Q1 25 | 1.3% | 2.0% | ||
| Q4 24 | 1.3% | 1.8% | ||
| Q3 24 | 3.2% | 3.5% | ||
| Q2 24 | 3.2% | 3.1% | ||
| Q1 24 | 3.3% | 3.8% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | 12.67× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.31× | ||
| Q1 24 | 1.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
SYNA
| Enterprise And Automotive Product Applications | $161.1M | 53% |
| Internet Of Things Product Applications | $93.2M | 31% |
| Mobile Product Applications | $48.2M | 16% |
